Author Archives: april@madhedgefundtrader.com

Champagne or Sham Pain?

You can almost hear the champagne corks popping as Amgen (AMGN) just notched all-time highs and sits comfortably in the portfolios of risk-averse institutions and dividend disciples alike. But in biotech, comfort can be deceptive. Beneath the surface, a patent cliff is forming, a tax storm is brewing, and the pipeline looks more “under renovation” […]